IPP Bureau
Syngene locks in Bristol Myers Squibb alliance through 2035
By IPP Bureau - January 20, 2026
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
Mahajan Imaging & Labs launches AI-driven blood test to detect Alzheimer’s early
By IPP Bureau - January 20, 2026
Over 8.8?million Indians aged 60 and above currently live with dementia,
Manthan 2026 wraps up, spotlighting India’s life sciences & clinical research future
By IPP Bureau - January 20, 2026
India in the Changing Landscape of Life-Sciences Research & Development
IRLAB Therapeutics teams up with Biomia to advance novel CNS drug candidates
By IPP Bureau - January 20, 2026
BorderPlus unveils AI-powered nurse companion at German Nursing Career Fair in Kochi
By IPP Bureau - January 20, 2026
The AI Nurse Companion, designed as a language-first learning platform, allows students to gain real-world German language proficiency through immersive practice
Torrent Pharma secures Rs. 12,500 crore for JB Chemicals takeover
By IPP Bureau - January 18, 2026
The capital was raised via multiple-tenure non-convertible debentures (NCDs) and commercial papers
JB Pharma Q3 FY26 PAT up by 22% to Rs. 198 Cr
By IPP Bureau - January 18, 2026
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
Bayer welcomes the U.S. Supreme Court decision to review Durnell case in the Roundup litigation
By IPP Bureau - January 17, 2026
Favorable outcome would contribute to significantly containing the Roundup litigation as the company continues its multi-pronged strategy
HDFC Bank to rally 1,500 staff at Tata Mumbai Marathon 2026 to drive cancer awareness
By IPP Bureau - January 17, 2026
The initiative is being led through the Bank’s CSR programme, Parivartan, in partnership with the Indian Cancer Society
EU clears Eylea 8 mg for retinal vein occlusion, expanding use of long-acting eye therapy
By IPP Bureau - January 17, 2026
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
Rakuten Medical teams up with LOTTE Biologics to boost production of innovative cancer therapy
By IPP Bureau - January 17, 2026
LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates
Agno Pharma acquires Actylis Eugene, expanding US API manufacturing footprint
By IPP Bureau - January 17, 2026
The Eugene facility, with more than 20 years of history, houses a 16,000-square-foot R&D lab and a newly constructed 30,000-square-foot manufacturing facility
Gradalis’ Vigil therapy dramatically extends survival in advanced ovarian cancer
By IPP Bureau - January 17, 2026
The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer
Boston Scientific to acquire Penumbra in $14.5 billion deal
By IPP Bureau - January 17, 2026
Penumbra projects fourth-quarter revenue growth of 21.4% to 22.0%, with full-year 2025 revenue expected to reach approximately $1.4 billion
Miach Orthopaedics’ BEAR implant gains FDA label claim for reduced arthritis risk
By IPP Bureau - January 17, 2026
The BEAR Implant is the first sports medicine device to carry a label claim related to lowering PTOA risk
